Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
83.97
-1.28 (-1.50%)
At close: Jul 29, 2025, 4:00 PM
82.35
-1.62 (-1.93%)
After-hours: Jul 29, 2025, 4:56 PM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 92 employees as of December 31, 2024. The number of employees increased by 59 or 178.79% compared to the previous year.
Employees
92
Change (1Y)
59
Growth (1Y)
178.79%
Revenue / Employee
n/a
Profits / Employee
-$2,154,620
Market Cap
4.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 92 | 59 | 178.79% |
| Dec 31, 2023 | 33 | 8 | 32.00% |
| Dec 31, 2022 | 25 | 5 | 25.00% |
| Dec 31, 2021 | 20 | 3 | 17.65% |
| Dec 31, 2020 | 17 | 5 | 41.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLNO News
- 19 days ago - Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewsWire
- 19 days ago - Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewsWire
- 19 days ago - Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 - GlobeNewsWire
- 5 weeks ago - Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results - GlobeNewsWire